The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Avacta's preCision platform is a proprietary payload delivery system designed to concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.

Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, ...

Creative Biolabs, a leader in viral vector engineering and immunotherapy solutions, has announced the expansion of its ...

The tumor microenvironment (TME) is a complex ecosystem whose immunosuppressive nature often causes resistance to cancer immunotherapy in solid malignancies. This editorial features the articles ...

1Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland.

Short-Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared with Standard of Care (SAVE): A Randomized Clinical Trial Pancreatic ductal adenocarcinoma (PDAC) is the third ...

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the University of Hong Kong has constructed the world's largest multi-omics ...